Close Menu

NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to the autologous CAR T-cell therapy axicabtagene ciloleucel (Gilead's Yescarta) as a treatment for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.